ABT-751
As of the edition of 20 October 2026, ABT-751 is a small molecule: went quiet in 2015; acts on TUBB, TUBB1 and TUBB2A and 7 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2015
- Kind
- Small molecule
- Registered trials
- 10, 3 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Blood and lymph; Digestive system; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TUBB8B | Tubulin beta 8B | A6NNZ2 |
| TUBB4A | Tubulin beta-4A chain | P04350 |
| TUBB | Tubulin beta chain | P07437 |
| TUBB4B | Tubulin beta-4B chain | P68371 |
| TUBB3 | Tubulin beta-3 chain | Q13509 |
| TUBB2A | Tubulin beta-2A chain | Q13885 |
| TUBB8 | Tubulin beta-8 chain | Q3ZCM7 |
| TUBB6 | Tubulin beta-6 chain | Q9BUF5 |
| TUBB2B | Tubulin beta-2B chain | Q9BVA1 |
| TUBB1 | Tubulin beta-1 chain | Q9H4B7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 8 | 5 | 0 | 3 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Abbott | Lead sponsor of trials | 2002 to now |